APA

Al-Batran S., Hofheinz R. D., Pauligk C., Kopp H., Haag G. M., Luley K. B., Meiler J., Homann N., Lorenzen S., Schmalenberg H., Probst S., Koenigsmann M., Egger M., Prasnikar N., Caca K., Trojan J., Martens U. M., Block A., Fischbach W., Mahlberg R., Clemens M., Illerhaus G., Zirlik K., Behringer D. M., Schmiegel W., Pohl M., Heike M., Ronellenfitsch U., Schuler M., Bechstein W. O., Königsrainer A., Gaiser T., Schirmacher P., Hozaeel W., Reichart A., Goetze T. O., Sievert M., Jäger E., Mönig S. & Tannapfel A. (20170529). Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. : The Lancet. Oncology.

Chicago

Al-Batran Salah-Eddin, Hofheinz Ralf D, Pauligk Claudia, Kopp Hans-Georg, Haag Georg Martin, Luley Kim Barbara, Meiler Johannes, Homann Nils, Lorenzen Sylvie, Schmalenberg Harald, Probst Stephan, Koenigsmann Michael, Egger Matthias, Prasnikar Nicole, Caca Karel, Trojan Jörg, Martens Uwe M, Block Andreas, Fischbach Wolfgang, Mahlberg Rolf, Clemens Michael, Illerhaus Gerald, Zirlik Katja, Behringer Dirk M, Schmiegel Wolff, Pohl Michael, Heike Michael, Ronellenfitsch Ulrich, Schuler Martin, Bechstein Wolf O, Königsrainer Alfred, Gaiser Timo, Schirmacher Peter, Hozaeel Wael, Reichart Alexander, Goetze Thorsten O, Sievert Mark, Jäger Elke, Mönig Stefan and Tannapfel Andrea. 20170529. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. : The Lancet. Oncology.

Harvard

Al-Batran S., Hofheinz R. D., Pauligk C., Kopp H., Haag G. M., Luley K. B., Meiler J., Homann N., Lorenzen S., Schmalenberg H., Probst S., Koenigsmann M., Egger M., Prasnikar N., Caca K., Trojan J., Martens U. M., Block A., Fischbach W., Mahlberg R., Clemens M., Illerhaus G., Zirlik K., Behringer D. M., Schmiegel W., Pohl M., Heike M., Ronellenfitsch U., Schuler M., Bechstein W. O., Königsrainer A., Gaiser T., Schirmacher P., Hozaeel W., Reichart A., Goetze T. O., Sievert M., Jäger E., Mönig S. and Tannapfel A. (20170529). Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. : The Lancet. Oncology.

MLA

Al-Batran Salah-Eddin, Hofheinz Ralf D, Pauligk Claudia, Kopp Hans-Georg, Haag Georg Martin, Luley Kim Barbara, Meiler Johannes, Homann Nils, Lorenzen Sylvie, Schmalenberg Harald, Probst Stephan, Koenigsmann Michael, Egger Matthias, Prasnikar Nicole, Caca Karel, Trojan Jörg, Martens Uwe M, Block Andreas, Fischbach Wolfgang, Mahlberg Rolf, Clemens Michael, Illerhaus Gerald, Zirlik Katja, Behringer Dirk M, Schmiegel Wolff, Pohl Michael, Heike Michael, Ronellenfitsch Ulrich, Schuler Martin, Bechstein Wolf O, Königsrainer Alfred, Gaiser Timo, Schirmacher Peter, Hozaeel Wael, Reichart Alexander, Goetze Thorsten O, Sievert Mark, Jäger Elke, Mönig Stefan and Tannapfel Andrea. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. : The Lancet. Oncology. 20170529.